Jump to navigation Jump to search

Clinical data
  • X
Routes of
ATC code
Legal status
Legal status
  • Schedule III (US), Schedule IV (CA)
Pharmacokinetic data
Elimination half-life? days
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass352.5156 g/mol

WikiDoc Resources for Quinbolone


Most recent articles on Quinbolone

Most cited articles on Quinbolone

Review articles on Quinbolone

Articles on Quinbolone in N Eng J Med, Lancet, BMJ


Powerpoint slides on Quinbolone

Images of Quinbolone

Photos of Quinbolone

Podcasts & MP3s on Quinbolone

Videos on Quinbolone

Evidence Based Medicine

Cochrane Collaboration on Quinbolone

Bandolier on Quinbolone

TRIP on Quinbolone

Clinical Trials

Ongoing Trials on Quinbolone at Clinical Trials.gov

Trial results on Quinbolone

Clinical Trials on Quinbolone at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Quinbolone

NICE Guidance on Quinbolone


FDA on Quinbolone

CDC on Quinbolone


Books on Quinbolone


Quinbolone in the news

Be alerted to news on Quinbolone

News trends on Quinbolone


Blogs on Quinbolone


Definitions of Quinbolone

Patient Resources / Community

Patient resources on Quinbolone

Discussion groups on Quinbolone

Patient Handouts on Quinbolone

Directions to Hospitals Treating Quinbolone

Risk calculators and risk factors for Quinbolone

Healthcare Provider Resources

Symptoms of Quinbolone

Causes & Risk Factors for Quinbolone

Diagnostic studies for Quinbolone

Treatment of Quinbolone

Continuing Medical Education (CME)

CME Programs on Quinbolone


Quinbolone en Espanol

Quinbolone en Francais


Quinbolone in the Marketplace

Patents on Quinbolone

Experimental / Informatics

List of terms related to Quinbolone

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Quinbolone (Anabolicum Vister) is an anabolic steroid with weak androgenic effects. It was developed by Parke Davis in an attempt to create a viable orally-administered anabolic steroid with little or no liver toxicity.

The drug is atypical in that steroid molecules are usually only given officially distinct names when there is a permanent structural difference between the parent molecule and itself. Quinbolone, however, differs from its parent molecule (boldenone) solely by the addition of an easily removed cyclopentenyl ether group.

Most orally administered anabolic steroids function by having an alkylated 17α-carbon atom, which prevents first-pass metabolism by the liver. This approach does, however, give the drug a high hepatotoxicity. Quinbolone is not 17α-alkylated; instead it has increased oral bioavailability due to its cyclopentenyl ether group. This allows the drug to be fully dissolved in an oil base, which is then absorbed into the lymphatic system via the large intestine, from which it travels into the blood. Once there the ester group detaches and the relatively inactive quinbolone becomes boldenone, which then reacts with the androgen receptor of any muscles it comes into contact with.

Quinbolone itself has very few androgenic effects, and most of what it does have are a result of its conversion to boldenone and its metabolites. This, combined with its unusual route of absorption, provides the drug with highly variable results, meaning that large quantities of the drug (100-200mgs per day) must be taken in order to maintain high enough concentrations in the blood for noticeable and consistent effects. The cost and inconvenience of this meant that quinbolone never proved commercially successful, and its clinical applications were fulfilled by alternative, more effective, steroids. Its illicit usage in bodybuilding and athletics likewise proved limited, though drug tests are still used to detect its metabolites as it remains a banned substance for most competitive sports.

See also

Template:Anabolic steroids

Template:WikiDoc Sources